New Delhi, April 4 – India’s drug regulators are increasing their oversight of rapidly growing weight-loss and diabetes therapies, particularly GLP-1 receptor agonists, amid rising demand and the anticipated entry of cheaper generic versions into the domestic market.This move comes as the...
New Delhi, April 1 – The Controller General of Drugs in India has increased regulatory scrutiny against the unauthorized sale and promotion of drugs for type 2 diabetes, also known as GLP-1 drugs, the government said on Wednesday.In recent weeks, 49 businesses across the country, including...
cardiology
diabetes
drug marketing
drug regulation
drug sales
endocrinologists
glp-1 drugs
glucagon-like peptide-1 receptor agonists
india
internalmedicine
medical specialties
pharmaceuticals
prescription drugs
regulatory inspections
type 2 diabetes
weight loss
New Delhi, March 24 To ensure ethical pharmaceutical practices in the supply chain of weight-loss drugs of the GLP-1 class, the Drugs Controller General of India (DCGI) has intensified its regulatory surveillance against the unauthorized sale and promotion of the medications.To this end...